Kynam Capital Management has significantly reduced its stake in Viridian Therapeutics (VRDN), selling nearly 2.96 million shares in Q4 2026 for approximately $81.11 million. This transaction, revealed in a recent SEC filing, brings Kynam’s holding in Viridian down to 2.92% of its 13F reportable assets. Despite this reduction, Viridian’s stock has surged 76% over the past year, far outpacing the S&P 500’s 15% gain.
The sale reflects a strategic move to manage risk after a substantial stock appreciation, rather than a loss of confidence in Viridian’s potential. The company is gearing up for critical milestones, including a PDUFA date for its lead candidate, veligrotug, and multiple Phase 3 readouts for VRDN-003. While R&D expenses have risen significantly, Viridian maintains a solid balance sheet with approximately $875 million in cash.
For investors, this stake trimming indicates a recalibration of risk exposure while still maintaining a position in a promising biotech pipeline. Upcoming clinical data will be crucial in determining the stock’s trajectory moving forward.
Source: fool.com